Patents by Inventor Anthony Cerami

Anthony Cerami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210107942
    Abstract: The present invention provides peptides an peptide analogs that have tissue protective activities while having little or no potentionally undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: May 19, 2020
    Publication date: April 15, 2021
    Inventors: Michael Brines, Anthony Cerami
  • Patent number: 10864253
    Abstract: Provided herein are peptides and peptide analogs that have tissue protective activities. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 15, 2020
    Assignee: Araim Pharmaceuticals, Inc.
    Inventors: Michael Brines, Anthony Cerami
  • Publication number: 20200360476
    Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesireable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: December 20, 2019
    Publication date: November 19, 2020
    Inventors: Anthony Cerami, Michael Brines
  • Publication number: 20200110087
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 9, 2020
    Inventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
  • Patent number: 10539563
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Grant
    Filed: September 4, 2018
    Date of Patent: January 21, 2020
    Assignee: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
  • Publication number: 20190134156
    Abstract: Provided herein are peptides and peptide analogs that have tissue protective activities. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 9, 2019
    Inventors: Michael Brines, Anthony Cerami
  • Publication number: 20190016769
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 17, 2019
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
  • Publication number: 20190004044
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Application
    Filed: September 4, 2018
    Publication date: January 3, 2019
    Inventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
  • Patent number: 10100096
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: October 16, 2018
    Assignee: Araim Pharmaceuticals, Inc.
    Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
  • Patent number: 10078080
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: September 18, 2018
    Assignee: ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC
    Inventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
  • Publication number: 20170234869
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Application
    Filed: April 4, 2017
    Publication date: August 17, 2017
    Applicant: Academisch Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Leendert Adrianus Trouw, Anthony Cerami, Thomas Willem Huizinga, Jing Shi, Reinaldus Everardus Maria Toes, Petrus Antonius Veelen
  • Publication number: 20170232066
    Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: January 30, 2017
    Publication date: August 17, 2017
    Inventors: Anthony CERAMI, Michael BRINES
  • Patent number: 9632084
    Abstract: Antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the diagnosis and possibly pathogenesis in arthritis. Described are means and methods for determining antibodies against homocitrulline-containing proteins or carbamylated proteins/peptides (anti-CarP) for the classification of individuals suffering from, or at risk of suffering from, arthritis.
    Type: Grant
    Filed: February 1, 2012
    Date of Patent: April 25, 2017
    Inventors: Leendert Adrianus Trouw, Reinaldus Everardus Maria Toes, Thomas Willem Johannes Huizinga, Petrus Antonius van Veelen, Anthony Cerami, Jing Shi
  • Patent number: 9580465
    Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoetic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: February 28, 2017
    Assignee: Araim Pharmaceuticals, Inc.
    Inventors: Anthony Cerami, Michael Brines
  • Publication number: 20160244498
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: May 5, 2016
    Publication date: August 25, 2016
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
  • Publication number: 20160168199
    Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: July 16, 2014
    Publication date: June 16, 2016
    Inventors: Michael Brines, Anthony Cerami
  • Patent number: 9340598
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: May 17, 2016
    Assignee: Araim Pharmaceuticals, Inc.
    Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
  • Publication number: 20150239932
    Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoetic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.
    Type: Application
    Filed: September 30, 2014
    Publication date: August 27, 2015
    Inventors: Anthony CERAMI, Michael BRINES
  • Publication number: 20150152156
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: February 10, 2015
    Publication date: June 4, 2015
    Inventors: Anthony Cerami, Michael Brines, Thomas Coleman
  • Publication number: 20140323401
    Abstract: The present invention is directed to novel tissue protective peptides. The tissue protective peptides of the invention may bind to a tissue protective receptor complex. In particular, the present invention is drawn to tissue protective peptides derived from or sharing consensus sequences with portions of cytokine receptor ligands, including Erythropoietin (EPO), that are not involved in the binding of the ligand to the receptor complex, e.g., to the EPO receptor homodimer. Accordingly, the tissue protective peptides of the invention are derived from the amino acid sequences of regions of cytokine receptor ligands that are generally located on or within the region of the ligand protein that is opposite of the receptor complex, i.e., are generally derived from amino acid sequences of regions of the ligand protein that face away from the receptor complex while the ligand is bound to the receptor.
    Type: Application
    Filed: April 8, 2014
    Publication date: October 30, 2014
    Applicant: Araim Pharmaceuticals, Inc.
    Inventors: Anthony CERAMI, Michael BRINES, Thomas COLEMAN